Location
University of Nevada Las Vegas, Student Union Ball Room
Start Date
6-8-2008 9:00 AM
End Date
6-8-2008 12:00 PM
Description
Despite major improvements in imaging, radiation, and surgery, the prognosis for patients with Glioblastoma multiforme (GBM) remains clinically challenging. New treatment strategies are badly needed to reduce the mortality and morbidity associated with this disease. The resistance of these tumors to conventional treatments makes GBM patients ideal candidates for molecularly targeted therapies and several agents are currently being developed(1). Because GBM is genetically heterogeneous, combination therapies or the use of multikinase inhibitors are more likely to achieve the greatest therapeutic benefit(2,3). However, genes that can be productively targeted for effective therapies in patients remain to be identified. The overall objective of this project was to better understand the signaling pathways driving cell survival so that new targets can be identified in gliomas. These studies will lead to an increased understanding of the proteins that are altered in this disease and should provide promising opportunities to develop better treatment strategies based on specific molecular targets.
Two parallel pathways, which are both activated in GBM, converge on downstream survival signaling cascades. Studies have demonstrated that blocking only one pathway often leads to a transient response (e.g., delayed time to progression), but tumors eventually progress(4). More effective therapies are likely to be those that inhibit more than one target or pathway(5). Targeting antiapoptotic Bcl-2 proteins in combination with RAS/MAPK or AKT/mTOR inhibition is a rationale approach.
To determine if inhibiting both the RAS/MAPK and AKT/mTOR pathways in combination results in increased apoptosis in glioma cells, I compared the level of apoptosis in cells treated with each inhibitor alone and in combination. Treatment of glioma cells with a MEK inhibitor in combination with a PI(3)K inhibitor has not previously been reported and therefore represents a new approach in the field. We already know that just inhibiting RAS/MAPK or AKT/mTOR alone results in cell cycle arrest but not death. I tested the effect on cell death when combining the inhibitors of both pathways, and saw an increase in cell death. I determined the growth inhibitory and apoptotic sensitivity of several human glioma cell lines to inhibition of both RAS/MAPK and AKT/mTOR pathways. Due to the heterogeneous nature of GBM, I predicted and saw that these cell lines display varying levels of sensitivity to MEK/PI(3)K inhibition. These differences can then be used in the future to further define the mechanism(s) by which the AKT and MAPK pathways mediate survival signaling in glioma cells.
Keywords
AKT/mTOR inhibition; Antiapoptotic Bcl-2 proteins; Brain cancer; Cancer treatments; Glioblastoma multiforme (GBM); RAS/MAPK inhibition
Disciplines
Oncology
Language
English
Characterizing and inhibiting two pathways activated in Glioblastoma Multiforme
University of Nevada Las Vegas, Student Union Ball Room
Despite major improvements in imaging, radiation, and surgery, the prognosis for patients with Glioblastoma multiforme (GBM) remains clinically challenging. New treatment strategies are badly needed to reduce the mortality and morbidity associated with this disease. The resistance of these tumors to conventional treatments makes GBM patients ideal candidates for molecularly targeted therapies and several agents are currently being developed(1). Because GBM is genetically heterogeneous, combination therapies or the use of multikinase inhibitors are more likely to achieve the greatest therapeutic benefit(2,3). However, genes that can be productively targeted for effective therapies in patients remain to be identified. The overall objective of this project was to better understand the signaling pathways driving cell survival so that new targets can be identified in gliomas. These studies will lead to an increased understanding of the proteins that are altered in this disease and should provide promising opportunities to develop better treatment strategies based on specific molecular targets.
Two parallel pathways, which are both activated in GBM, converge on downstream survival signaling cascades. Studies have demonstrated that blocking only one pathway often leads to a transient response (e.g., delayed time to progression), but tumors eventually progress(4). More effective therapies are likely to be those that inhibit more than one target or pathway(5). Targeting antiapoptotic Bcl-2 proteins in combination with RAS/MAPK or AKT/mTOR inhibition is a rationale approach.
To determine if inhibiting both the RAS/MAPK and AKT/mTOR pathways in combination results in increased apoptosis in glioma cells, I compared the level of apoptosis in cells treated with each inhibitor alone and in combination. Treatment of glioma cells with a MEK inhibitor in combination with a PI(3)K inhibitor has not previously been reported and therefore represents a new approach in the field. We already know that just inhibiting RAS/MAPK or AKT/mTOR alone results in cell cycle arrest but not death. I tested the effect on cell death when combining the inhibitors of both pathways, and saw an increase in cell death. I determined the growth inhibitory and apoptotic sensitivity of several human glioma cell lines to inhibition of both RAS/MAPK and AKT/mTOR pathways. Due to the heterogeneous nature of GBM, I predicted and saw that these cell lines display varying levels of sensitivity to MEK/PI(3)K inhibition. These differences can then be used in the future to further define the mechanism(s) by which the AKT and MAPK pathways mediate survival signaling in glioma cells.
Comments
Abstract & poster